Serum uric acid, influence of sacubitril/valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF

被引：0

作者：

Selvaraj, S. ^{[1
]}

Claggett, B. L. ^{[2
]}

Veldhuisen, D. V. ^{[3
]}

Anand, I. S. ^{[4
]}

Pieske, B. ^{[5
]}

Rouleau, J. L. ^{[6
]}

Zile, M. R. ^{[7
]}

Shi, V. C. ^{[8
]}

Lelkowite, M. P. ^{[8
]}

McMurray, J. J., V ^{[9
]}

Solomon, S. D. ^{[2
]}

机构：

[1] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA

[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[3] Univ Med Ctr Groningen, Groningen, Netherlands

[4] Univ Minnesota, Minneapolis, MN USA

[5] German Ctr Cardiovasc Res, Berlin, Germany

[6] Univ Montreal, Montreal, PQ, Canada

[7] Med Univ South Carolina, Charleston, SC 29425 USA

[8] Novartis, E Hanover, NJ USA

[9] Cardiovasc Res Ctr Glasgow, Glasgow, Lanark, Scotland

来源：

EUROPEAN HEART JOURNAL | 2020年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1066 / 1066

页数：1

共 50 条

[21] Global differences in heart failure with preserved ejection fraction: the paragon-hf trial
Tromp, J.
Clagget, B. L.
Jhund, P.
Kober, L.
Widimsky, J.
Chopra, V
Ge, J.
Maggioni, A. P.
Martinez, F.
Zannad, F.
Lefkowitz, M. P.
Shi, V. C.
McMurray, J. J., V
Solomon, S. D.
Lam, C. S. P.
EUROPEAN HEART JOURNAL, 2020, 41 : 850 - 850
[22] Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial
Ferreira, Joao Pedro
Claggett, Brian L.
Liu, Jiankang
Desai, Akshay S.
Pfeffer, Marc A.
Anand, Inder S.
Van Veldhuisen, Dirk J.
Kober, Lars
Cleland, John G. F.
Rouleau, Jean L.
Packer, Milton
Zile, Michael R.
Shi, Victor C.
Lefkowitz, Martin P.
Shah, Sanjiv J.
Vardeny, Orly
Zannad, Faiez
Solomon, Scott D.
McMurray, John J. V.
EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (05) : 776 - 784
[23] Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial
Solomon, Scott D.
Rizkala, Adel R.
Lefkowitz, Martin P.
Shi, Victor C.
Gong, JianJian
Anavekar, Nagesh
Anker, Stefan D.
Arango, Juan L.
Arenas, Jose L.
Atar, Dan
Ben-Gal, Turia
Boytsov, Sergey A.
Chen, Chen-Huan
Chopra, Vijay K.
Cleland, John
Comin-Colet, Josep
Duengen, Hans-Dirk
Echeverria Correa, Luis E.
Filippatos, Gerasimos
Flammer, Andreas J.
Galinier, Michel
Godoy, Armando
Goncalvesova, Eva
Janssens, Stefan
Katova, Tzvetana
Kober, Lars
Lelonek, Malgorzata
Linssen, Gerard
Lund, Lars H.
O'Meara, Eileen
Merkely, Bela
Milicic, Davor
Oh, Byung-Hee
Perrone, Sergio V.
Ranjith, Naresh
Saito, Yoshihiko
Saraiva, Jose F.
Shah, Sanjiv
Seferovic, Petar M.
Senni, Michele
Sibulo, Antonio S., Jr.
Sim, David
Sweitzer, Nancy K.
Taurio, Jyrki
Vinereanu, Dragos
Vrtovec, Bojan
Widimsky, Jiri
Yilmaz, Mehmet B.
Zhou, Jingmin
Zweiker, Robert
CIRCULATION-HEART FAILURE, 2018, 11 (07)
[24] Neutrophil/lymphocyte ratio and outcomes in patients with heart failure and preserved ejection fraction: An analysis of PARAGON-HF
Mooney, L.
Jhund, P. S.
Vaduganathan, M.
Comin-Colet, J.
Desai, A. S.
Lefkowitz, M. P.
Rizkala, A. P.
Rouleau, J. L.
Senni, M.
Sweitzer, N.
Van Veldhuisen, D. J.
Zannad, F.
Lang, N.
Solomon, S. D.
Mcmurray, J. John
EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 11 - 11
[25] Letter by Tuncez and Gurses Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF"
Tuncez, Abdullah
Gurses, Kadri Murat
CIRCULATION, 2025, 151 (06) : e37 - e37
[26] PARAGON-HF - considerations for potential use of sacubitril-valsartan in real-world heart failure with mildly reduced ejection fraction
Lund, Lars H.
Savarese, Gianluigi
JOURNAL OF CARDIAC FAILURE, 2019, 25 (12) : 1012 - 1013
[27] Impact of Chronic Obstructive Pulmonary Disease on Outcomes in Heart Failure With Preserved Ejection Fraction: An Analysis of PARAGON-HF
Mooney, Leanne
Jhund, Pardeep S.
Anand, Inder S.
Desai, Akshay S.
Maggioni, Aldo P.
Rouleau, Jean L.
Swedberg, Karl B.
Van Veldhuisen, Dirk J.
Zile, Michael R.
Solomon, Scott
McMurray, John J.
CIRCULATION, 2020, 142
[28] Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
Vaduganathan, Muthiah
Mentz, Robert J.
Claggett, Brian L.
Miao, Zi Michael
Kulac, Ian J.
Ward, Jonathan H.
Hernandez, Adrian F.
Morrow, David A.
Starling, Randall C.
Velazquez, Eric J.
Williamson, Kristin M.
Desai, Akshay S.
Zieroth, Shelley
Lefkowitz, Martin
McMurray, John J., V
Braunwald, Eugene
Solomon, Scott D.
EUROPEAN HEART JOURNAL, 2023, 44 (31) : 2982 - 2993
[29] Efficacy and safety of sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction according to background MRA therapy: a pooled analysis of PARAGLIDE-HF and PARAGON-HF
Inciardi, Riccardo Maria
Mentz, R. J.
Claggett, B.
Ward, J. H.
Hernandez, A. F.
Morrow, D. A.
Starling, R. C.
Velazquez, E. J.
Desay, A. S.
Zieroth, S.
Lefkowitz, M.
Mcmurray, J. J. V.
Braunwald, E.
Solomon, S. D.
Vaduganathan, M.
EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 67 - 67
[30] Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
Selvaraj, Senthil
Claggett, Brian L.
Packer, Milton
Zannad, Faiez
Anand, Inder S.
Pieske, Burkert
Zhao, Ziqiang
Shi, Victor C.
Lefkowitz, Martin P.
McMurray, John J., V
Solomon, Scott D.
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (17):

← 1 2 3 4 5 →